PhageTech, Inc.’s proprietary technology consists of engineered bacteriophages bonded to a proprietary material developed and patented by the University of California, Irvine and licensed to PhageTech, Inc.
PhageTech, Inc.’s bioconducting materials are antibody-free, reagent-free, label-free and nearly instantaneous. The result is a biologically active and electrically passive multi-channel biosensor, creating a quantifiable signal when in contact with specific disease biomarkers. It is capable of performing multiple simultaneous assays without complex sample processing. A fluid-in and data-out model eliminates the need for any special training, lab equipment or capital equipment. Each biosensor can be read by a self-powered handheld reader, with patient results instantly displayed using a smartphone app and securely transported to the cloud.